NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

If you're developing a healthtech product, understanding NICE's priorities is crucial. For 2024/25, NICE is focussing on innovations addressing: ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

A list of downloadable documents created during development.

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 4:30pm, although timings may be subject to change. You will receive your ...

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer TA1041 19 February 2025 19 February 2025 Selpercatinib for previously treated RET ...

The meeting will take place via Zoom, a secure web conferencing tool. The meeting will run from 9:00am to 4:00pm, although this may be subject to change. Joining links and times for each ...

The meeting will take place as a webinar via Zoom, a secure web conferencing tool. This meeting will run from 10:00am to 1:00pm, although timings may be subject to change. You will receive your ...